Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Grail is a healthcare company whose mission is to detect cancer early, when it can be cured. Grail is focused on developing and commercializing pioneering breakthroughs in cancer screening and diagnostics, including Galleri®, a multi-cancer early detection (MCED) test. By combining expertise in cancer biology with advanced machine learning, data science, and population-scale clinical studies, Grail aims to reduce the global burden of cancer by providing tests that can screen for multiple types of cancer from a single blood draw.
Serves as the primary center for corporate leadership, research and development, data science, engineering, and key operational functions driving Grail's mission in early cancer detection.
State-of-the-art CLIA-certified and CAP-accredited laboratory facilities, advanced data science infrastructure, and modern, collaborative office spaces designed to foster innovation in genomic sequencing and cancer detection technologies.
Characterized by a mission-driven, innovative, and collaborative environment. Employees are typically passionate about the company's goal to significantly impact public health by transforming cancer screening and early detection. The culture emphasizes scientific rigor, urgency, and patient focus.
The Menlo Park headquarters is significant due to its proximity to world-class research institutions, a rich talent pool in biotech and technology, and the venture capital ecosystem, all of which are vital for Grail's growth and innovation leadership in the competitive field of cancer diagnostics.
Grail is expanding its global presence to support its mission of detecting cancer early worldwide. This includes establishing laboratory and operational capabilities in key international markets, conducting large-scale clinical studies with global partners (such as the NHS in the UK), engaging with international regulatory bodies, and building commercial infrastructure to make its cancer detection tests accessible to patients globally. Functions supported include clinical operations, research collaborations, market access, and commercial activities.
1525 O'Brien Drive
Menlo Park
CA
USA
Address: 4810 Emperor Blvd, Durham, NC 27703, USA
Supports large-scale clinical sample processing, assay development, and quality control. It enhances Grail's capacity for delivering its cancer detection tests across the United States and supports ongoing research efforts.
Address: 84 Eccleston Square, London, SW1V 1PX, United Kingdom
Drives Grail's expansion into international markets, fosters collaborations with healthcare systems like the UK's National Health Service (NHS), and supports the generation of real-world evidence for its multi-cancer early detection technology in diverse populations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, GRAIL' leadership includes:
GRAIL has been backed by several prominent investors over the years, including:
In the past year, Grail has focused on strengthening its executive leadership, particularly in finance, as it prepares for its planned divestiture from Illumina and continues to scale its operations and commercial efforts for its groundbreaking cancer detection technologies.
Discover the tools GRAIL uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Grail, Inc. typically uses a standardized email format for its employees, primarily utilizing the grail.com domain. The most common pattern involves the first initial followed by the last name.
[first_initial][last]@grail.com
Format
jdoe@grail.com
Example
85%
Success rate
Reuters • April 2, 2024
Illumina announced it has filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission for the proposed spinoff of its cancer diagnostic test maker Grail. This is a significant step in Illumina's plan to divest Grail as an independent company....more
PR Newswire • March 13, 2024
GRAIL presented new data demonstrating the ability of its Galleri multi-cancer early detection test to identify various cancers in asymptomatic individuals at earlier stages. The findings also highlighted improved efficiency in the diagnostic process following a positive Galleri test....more
Business Wire • January 9, 2024
GRAIL announced the appointment of Aaron L. Nelson as its new Chief Financial Officer. Nelson brings over two decades of financial leadership experience in the healthcare industry to support GRAIL's continued growth and commercialization of its early cancer detection technologies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including GRAIL, are just a search away.